<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; system</title>
	<atom:link href="http://www.tapanray.in/tag/system/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Big Pharma Fails Avoiding Drug Price ‘Control’? Even In The US? Why?</title>
		<link>http://www.tapanray.in/big-pharma-fails-avoiding-drug-price-control-even-in-the-us-why/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=big-pharma-fails-avoiding-drug-price-control-even-in-the-us-why</link>
		<comments>http://www.tapanray.in/big-pharma-fails-avoiding-drug-price-control-even-in-the-us-why/#comments</comments>
		<pubDate>Mon, 22 Aug 2022 00:00:49 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[ABBvie]]></category>
		<category><![CDATA[associations]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[competition]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[deals. Authorized]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Eldorado]]></category>
		<category><![CDATA[Game]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[generics competition]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[Medicare]]></category>
		<category><![CDATA[molecule]]></category>
		<category><![CDATA[negotiation]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Pay-for-delay]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[system]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Thicket]]></category>
		<category><![CDATA[United States]]></category>
		<category><![CDATA[US]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10699</guid>
		<description><![CDATA[It ultimately happened &#8211; even in the United States, as the US President signed a bill on August 16, 2022 that aims to reduce healthcare costs, alongside fighting climate change, besides raising taxes on the rich. This new law was enacted, despite &#8230; <a href="http://www.tapanray.in/big-pharma-fails-avoiding-drug-price-control-even-in-the-us-why/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/big-pharma-fails-avoiding-drug-price-control-even-in-the-us-why/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Time For Predictive Rather Than Reactive Pharma Strategy</title>
		<link>http://www.tapanray.in/time-for-predictive-rather-than-reactive-pharma-strategy/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=time-for-predictive-rather-than-reactive-pharma-strategy</link>
		<comments>http://www.tapanray.in/time-for-predictive-rather-than-reactive-pharma-strategy/#comments</comments>
		<pubDate>Mon, 15 Jun 2020 00:00:38 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Approach]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[Change]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[Digitalization]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[first in class]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[innovative]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[me-too]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[mindset]]></category>
		<category><![CDATA[molecule]]></category>
		<category><![CDATA[pathway]]></category>
		<category><![CDATA[predictive]]></category>
		<category><![CDATA[proactive]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reactive]]></category>
		<category><![CDATA[safe]]></category>
		<category><![CDATA[sailing]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[supply-chain]]></category>
		<category><![CDATA[system]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[traditional]]></category>
		<category><![CDATA[value-based]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10126</guid>
		<description><![CDATA[Traditionally, pharmaceutical industry, across the world, is mostly reactive &#8211; rather than proactive or predictive in its strategic approach &#8211; spanning across all its business domains. A large number of pharma players &#8211; both innovators and generic drug makers, formulate &#8230; <a href="http://www.tapanray.in/time-for-predictive-rather-than-reactive-pharma-strategy/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/time-for-predictive-rather-than-reactive-pharma-strategy/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma’s ‘Value Delivery System’ Still Tuned To A Self-serving Mode?</title>
		<link>http://www.tapanray.in/pharmas-value-delivery-system-still-tuned-to-a-self-serving-mode/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharmas-value-delivery-system-still-tuned-to-a-self-serving-mode</link>
		<comments>http://www.tapanray.in/pharmas-value-delivery-system-still-tuned-to-a-self-serving-mode/#comments</comments>
		<pubDate>Mon, 04 Feb 2019 00:00:07 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[core]]></category>
		<category><![CDATA[delivery]]></category>
		<category><![CDATA[dented]]></category>
		<category><![CDATA[doctor]]></category>
		<category><![CDATA[image]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[mode]]></category>
		<category><![CDATA[nonaherance]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[patient-centric]]></category>
		<category><![CDATA[patient-experience]]></category>
		<category><![CDATA[product-centric]]></category>
		<category><![CDATA[Pyramid]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reputation]]></category>
		<category><![CDATA[reverse]]></category>
		<category><![CDATA[self-serving]]></category>
		<category><![CDATA[system]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[value]]></category>
		<category><![CDATA[VDS]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9397</guid>
		<description><![CDATA[Just as any other industry, pharma business is also primarily a ‘value delivery system.’ Its each and every employee need to understand and internalize this basic philosophy of the business. This organizational mindset needs to be created by the very &#8230; <a href="http://www.tapanray.in/pharmas-value-delivery-system-still-tuned-to-a-self-serving-mode/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharmas-value-delivery-system-still-tuned-to-a-self-serving-mode/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Patients’ Trust And Pharma Remain Strange Bedfellows?</title>
		<link>http://www.tapanray.in/patients-trust-and-pharma-remain-strange-bedfellows/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=patients-trust-and-pharma-remain-strange-bedfellows</link>
		<comments>http://www.tapanray.in/patients-trust-and-pharma-remain-strange-bedfellows/#comments</comments>
		<pubDate>Mon, 03 Sep 2018 00:00:11 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[bedfellows]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[Council]]></category>
		<category><![CDATA[Department]]></category>
		<category><![CDATA[doctor]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[gap]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[MCI]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Prime]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[relationship]]></category>
		<category><![CDATA[strange]]></category>
		<category><![CDATA[system]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[trust]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[uneasy]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9129</guid>
		<description><![CDATA[Like many other industries, pharmaceutical companies too often talk about improving focus on effective ‘stakeholder-relationship management’. The doctors obviously form an integral part of this process. There is nothing wrong with it. Nevertheless, serious concern of ‘conflict of interest’ between &#8230; <a href="http://www.tapanray.in/patients-trust-and-pharma-remain-strange-bedfellows/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/patients-trust-and-pharma-remain-strange-bedfellows/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>&#8216;Rigged&#8217; Payment System Limits Biosimilar Access</title>
		<link>http://www.tapanray.in/rigged-payment-system-limits-biosimilar-access/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=rigged-payment-system-limits-biosimilar-access</link>
		<comments>http://www.tapanray.in/rigged-payment-system-limits-biosimilar-access/#comments</comments>
		<pubDate>Mon, 02 Apr 2018 00:00:05 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Biologic]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[branded]]></category>
		<category><![CDATA[commissioner]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[el dorado]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[Interchangeability]]></category>
		<category><![CDATA[large]]></category>
		<category><![CDATA[largest]]></category>
		<category><![CDATA[launch]]></category>
		<category><![CDATA[litigations]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[molecule]]></category>
		<category><![CDATA[original]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Payment]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[rigged]]></category>
		<category><![CDATA[small]]></category>
		<category><![CDATA[states]]></category>
		<category><![CDATA[system]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[United]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[Zarxio]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8908</guid>
		<description><![CDATA[As often discussed, market entry of biosimilars, in general, brings a new hope not just for many patients, but also to biosimilar drug manufacturers &#8211; planning to get marketing approvals of these drugs in the United States, the El Dorado &#8230; <a href="http://www.tapanray.in/rigged-payment-system-limits-biosimilar-access/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/rigged-payment-system-limits-biosimilar-access/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>SCM: Embracing Technology For Patients’ Safety</title>
		<link>http://www.tapanray.in/scm-embracing-technology-for-patients-safety/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=scm-embracing-technology-for-patients-safety</link>
		<comments>http://www.tapanray.in/scm-embracing-technology-for-patients-safety/#comments</comments>
		<pubDate>Sun, 17 Dec 2017 23:40:31 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[chain]]></category>
		<category><![CDATA[Combiflam]]></category>
		<category><![CDATA[D-Cold]]></category>
		<category><![CDATA[DGFT]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[DSCSA]]></category>
		<category><![CDATA[embracing]]></category>
		<category><![CDATA[harnessing]]></category>
		<category><![CDATA[identifier]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Leveraging]]></category>
		<category><![CDATA[management]]></category>
		<category><![CDATA[notification]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Product]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[SCM]]></category>
		<category><![CDATA[serialization]]></category>
		<category><![CDATA[Supply]]></category>
		<category><![CDATA[system]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[technology]]></category>
		<category><![CDATA[trace]]></category>
		<category><![CDATA[Track]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8646</guid>
		<description><![CDATA[Supply Chain Management (SCM) in the pharma industry is generally perceived as a logistic function, just in most other industries, involving the distribution of medicines from manufacturing plants, right up to pharma distributors. Thereafter, it becomes the responsibility of the &#8230; <a href="http://www.tapanray.in/scm-embracing-technology-for-patients-safety/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/scm-embracing-technology-for-patients-safety/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Should ‘Pharma Marketing’ Be In The Line of Fire?</title>
		<link>http://www.tapanray.in/should-pharma-marketing-be-in-the-line-of-fire/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=should-pharma-marketing-be-in-the-line-of-fire</link>
		<comments>http://www.tapanray.in/should-pharma-marketing-be-in-the-line-of-fire/#comments</comments>
		<pubDate>Sun, 26 Nov 2017 23:31:21 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA['condo']]></category>
		<category><![CDATA[ails]]></category>
		<category><![CDATA[Allegation]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[decision]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[fire]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[intrinsic]]></category>
		<category><![CDATA[line]]></category>
		<category><![CDATA[Malpractices]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[medication]]></category>
		<category><![CDATA[OTC]]></category>
		<category><![CDATA[prescription]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[serious]]></category>
		<category><![CDATA[support]]></category>
		<category><![CDATA[system]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[UHC]]></category>
		<category><![CDATA[value]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8570</guid>
		<description><![CDATA[Close to half a century ago, Peter Drucker &#8211; the Management Guru wrote: As the purpose of business is to create customers, any business enterprise has two basic functions: marketing and innovation. Drucker’s concept is so fundamental in nature that it will possibly never change, ever. That innovation &#8230; <a href="http://www.tapanray.in/should-pharma-marketing-be-in-the-line-of-fire/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/should-pharma-marketing-be-in-the-line-of-fire/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>An Evolving Paradigm of ‘Price-Value Model’ Of Pharma Value Delivery System</title>
		<link>http://www.tapanray.in/an-evolving-paradigm-of-price-value-model-of-pharma-value-delivery-system/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=an-evolving-paradigm-of-price-value-model-of-pharma-value-delivery-system</link>
		<comments>http://www.tapanray.in/an-evolving-paradigm-of-price-value-model-of-pharma-value-delivery-system/#comments</comments>
		<pubDate>Mon, 09 May 2016 00:00:25 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[alipogene]]></category>
		<category><![CDATA[delivery]]></category>
		<category><![CDATA[DNA]]></category>
		<category><![CDATA[Ebola]]></category>
		<category><![CDATA[evolving]]></category>
		<category><![CDATA[gene]]></category>
		<category><![CDATA[Glybera]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[map]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[model]]></category>
		<category><![CDATA[paradigm]]></category>
		<category><![CDATA[Price-Value]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[system]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[therapy]]></category>
		<category><![CDATA[tiparvovec)]]></category>
		<category><![CDATA[value]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7631</guid>
		<description><![CDATA[May 4, 2016 edition of the ‘MIT Technology Review’ published an interesting article carrying the headline, “The World’s Most Expensive Medicine Is a Bust”. The obvious question that floats at the top of mind: What is this most expensive drug &#8230; <a href="http://www.tapanray.in/an-evolving-paradigm-of-price-value-model-of-pharma-value-delivery-system/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/an-evolving-paradigm-of-price-value-model-of-pharma-value-delivery-system/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>NDDS as New Drug: Good for Patients, Great for Pharma</title>
		<link>http://www.tapanray.in/ndds-as-new-drug-good-for-patients-great-for-pharma/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=ndds-as-new-drug-good-for-patients-great-for-pharma</link>
		<comments>http://www.tapanray.in/ndds-as-new-drug-good-for-patients-great-for-pharma/#comments</comments>
		<pubDate>Mon, 13 Jan 2014 00:00:07 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2013]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[CR]]></category>
		<category><![CDATA[CT]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[delivery]]></category>
		<category><![CDATA[DPCO]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[DTAB]]></category>
		<category><![CDATA[FDC]]></category>
		<category><![CDATA[IND]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[MR]]></category>
		<category><![CDATA[NDA]]></category>
		<category><![CDATA[NDDS]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[rDNA]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[system]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[vaccines]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=4839</guid>
		<description><![CDATA[The Ministry of Health of India has reportedly decided to amend Rule 122 (E) of the Drugs and Cosmetics Rules, 1945 to categorize the New Drug Delivery Systems (NDDS), including ‘Controlled Release (CR)’ or ‘Modified Release (MR)’ formulations, whether a &#8230; <a href="http://www.tapanray.in/ndds-as-new-drug-good-for-patients-great-for-pharma/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/ndds-as-new-drug-good-for-patients-great-for-pharma/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma Marketing in India: 10 Chain Events to Catalyze a Paradigm Shift</title>
		<link>http://www.tapanray.in/pharma-marketing-in-india-10-chain-events-to-catalyze-a-paradigm-shift/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-marketing-in-india-10-chain-events-to-catalyze-a-paradigm-shift</link>
		<comments>http://www.tapanray.in/pharma-marketing-in-india-10-chain-events-to-catalyze-a-paradigm-shift/#comments</comments>
		<pubDate>Mon, 17 Jun 2013 00:00:23 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[Alibaba]]></category>
		<category><![CDATA[archaic]]></category>
		<category><![CDATA[assessment]]></category>
		<category><![CDATA[branded]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[cocoon]]></category>
		<category><![CDATA[commercial]]></category>
		<category><![CDATA[composite]]></category>
		<category><![CDATA[Cosmetic]]></category>
		<category><![CDATA[Coverage]]></category>
		<category><![CDATA[delivery]]></category>
		<category><![CDATA[differentiated]]></category>
		<category><![CDATA[distribution]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[effect]]></category>
		<category><![CDATA[faster]]></category>
		<category><![CDATA[Finance]]></category>
		<category><![CDATA[Free]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[herald]]></category>
		<category><![CDATA[Heralding]]></category>
		<category><![CDATA[HTA]]></category>
		<category><![CDATA[ICICI]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[insurance]]></category>
		<category><![CDATA[IPM]]></category>
		<category><![CDATA[leadership]]></category>
		<category><![CDATA[Lombard]]></category>
		<category><![CDATA[magic]]></category>
		<category><![CDATA[Malpractices]]></category>
		<category><![CDATA[Managing]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[mediclaim]]></category>
		<category><![CDATA[Metamorphosis]]></category>
		<category><![CDATA[MR]]></category>
		<category><![CDATA[MRs]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[of pharma]]></category>
		<category><![CDATA[outcomes]]></category>
		<category><![CDATA[paradigm]]></category>
		<category><![CDATA[payers]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[pharmacy-economics]]></category>
		<category><![CDATA[physicians]]></category>
		<category><![CDATA[Players]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[remedies]]></category>
		<category><![CDATA[Representatives]]></category>
		<category><![CDATA[sets]]></category>
		<category><![CDATA[skill]]></category>
		<category><![CDATA[Standard]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[system]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[technology]]></category>
		<category><![CDATA[transition]]></category>
		<category><![CDATA[UHC]]></category>
		<category><![CDATA[Universal]]></category>
		<category><![CDATA[value]]></category>
		<category><![CDATA[well]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2454</guid>
		<description><![CDATA[In the matured markets of the world pharmaceutical marketing is quite different in many respect as compared to India. Besides doctors, different sets of customer groups like, healthcare providers, patient advocacy groups, pharmacy benefit managers, clinical assessment authorities play various &#8230; <a href="http://www.tapanray.in/pharma-marketing-in-india-10-chain-events-to-catalyze-a-paradigm-shift/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-marketing-in-india-10-chain-events-to-catalyze-a-paradigm-shift/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
